Alle Fälle anzeigen
UPC APP 16366/2025
—·EP4183412: RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAME
- Verfahrensdetails
- Status—VerfahrensartVerfahrensantragKategorieRücknahmeanträge
- Parteien
- Kläger
- Pfizer, Inc.
- Pfizer Europe MA EEIG
- Pfizer B.V.
- Pfizer S.A.
- Pfizer Manufacturing Belgium NV
- Pfizer Service Company S.R.L.
- Pfizer Pharma GmbH
- Pfizer Limited
- Pfizer Corporation Austria GmbH
- Pfizer Aps
- Pfizer Oy
- Pfizer SAS
- Pfizer S.r.l.
- Laboratórios Pfizer, Lda.
- Pfizer AB
- Pfizer Luxembourg S.a.r.l.
Vertreter: Gareth Williams - Division
- Milan CD
- Richter
- Andrea Postiglione · Presiding Judge
- Anna-Lena Klein · Judge-Rapporteur
- Steen Wadskov-Hansen · Technically Qualified Judge
- Technology
- Biotechnology
- Sprache
- —
- Erste Entscheidung
- 22. Apr. 2025
Entscheidungen
- 2025-04-22ZurückgenommenApplication Rop 265
Milan Central Division procedural order granting Pfizer's application to withdraw a revocation action against GlaxoSmithKline Biologicals SA concerning EP 4 183 412 (RSV F protein vaccine patent), and a separately filed counterclaim for revocation in parallel Düsseldorf infringement proceedings (which had been referred to the Central Division). Pfizer and Glaxo had each filed applications to amend the patent; both revocation actions were withdrawn by Pfizer prior to closure of the written procedure. The court also ordered 60% reimbursement of court fees and confirmed each party bears its own costs.
Rechtsfragen:Withdrawal of revocation action (R. 265.1 RoP)Reimbursement of court fees (R. 370 RoP)Referral of counterclaim for revocation from local to central divisionApplication to amend patent
Dokumente
- 83A40873F1721B10D2423F4CB5182319_en.pdf2025-04-22EN